Molecular and Circulating Biomarkers in Patients with Glioblastoma

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Jul 9

PMID 35806478

Authors

Nadia Senhaji

Asmae Squalli Houssaini

Salma Lamrabet

Sara Louati

Sanae Bennis

Affiliations

Soon will be listed here.

Abstract

Glioblastoma is the most aggressive malignant tumor of the central nervous system with a low survival rate. The difficulty of obtaining this tumor material represents a major limitation, making the real-time monitoring of tumor progression difficult, especially in the events of recurrence or resistance to treatment. The identification of characteristic biomarkers is indispensable for an accurate diagnosis, the rigorous follow-up of patients, and the development of new personalized treatments. Liquid biopsy, as a minimally invasive procedure, holds promise in this regard. The purpose of this paper is to summarize the current literature regarding the identification of molecular and circulating glioblastoma biomarkers and the importance of their integration as a valuable tool to improve patient care.

Citing Articles

Transitioning from molecular methods to therapeutic methods: An in‑depth analysis of glioblastoma (Review).

Han H, Du A, Li J, Han H, Feng P, Zhu Y Oncol Rep. 2025; 53(4).

PMID: 40017136 PMC: 11894601. DOI: 10.3892/or.2025.8881.

Levels of Proangiogenic Molecules and Terminal Complement Complex C5b-9 in the Crown of Circulating sEVs in Patients with Recurrent Glioblastomas: Relationship with Tumor Molecular Characteristics.

Yunusova N, Tulendinov E, Svarovsky D, Ryabova A, Kondakova I, Ponomaryova A Curr Issues Mol Biol. 2025; 47(2).

PMID: 39996852 PMC: 11854864. DOI: 10.3390/cimb47020132.

Predictive and Prognostic Significance of Molecular Biomarkers in Glioblastoma.

Shah S, Nag A, Sachithanandam S, Lucke-Wold B Biomedicines. 2025; 12(12.

PMID: 39767571 PMC: 11727522. DOI: 10.3390/biomedicines12122664.

Proteomic Profiling of Pre- and Post-Surgery Saliva of Glioblastoma Patients: A Pilot Investigation.

Muntiu A, Moresi F, Vincenzoni F, Rossetti D, Iavarone F, Messana I Int J Mol Sci. 2024; 25(23).

PMID: 39684695 PMC: 11641718. DOI: 10.3390/ijms252312984.

TMEM35B as a novel biomarker for diagnosing gliomas.

Liang G, Lai X, Yan G, He W, Su L, Luo J Biomark Med. 2024; 18(24):1103-1111.

PMID: 39589905 PMC: 11654807. DOI: 10.1080/17520363.2024.2431480.

References

Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M . Long-term survival with glioblastoma multiforme. Brain. 2007; 130(Pt 10):2596-606. DOI: 10.1093/brain/awm204. View

Skog J, Wurdinger T, van Rijn S, Meijer D, Gainche L, Sena-Esteves M . Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008; 10(12):1470-6. PMC: 3423894. DOI: 10.1038/ncb1800. View

Clark O, Yen K, Mellinghoff I . Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer. Clin Cancer Res. 2016; 22(8):1837-42. PMC: 4834266. DOI: 10.1158/1078-0432.CCR-13-1333. View

Abou-El-Ardat K, Seifert M, Becker K, Eisenreich S, Lehmann M, Hackmann K . Comprehensive molecular characterization of multifocal glioblastoma proves its monoclonal origin and reveals novel insights into clonal evolution and heterogeneity of glioblastomas. Neuro Oncol. 2017; 19(4):546-557. PMC: 5464316. DOI: 10.1093/neuonc/now231. View

Svobodova Z, Kucerova J, Autebert J, Horak D, Bruckova L, Viovy J . Application of an improved magnetic immunosorbent in an Ephesia chip designed for circulating tumor cell capture. Electrophoresis. 2013; 35(2-3):323-9. DOI: 10.1002/elps.201300196. View

Esteller M, Hamilton S, Burger P, Baylin S, Herman J . Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 1999; 59(4):793-7. View

Kolostova K, Pospisilova E, Pavlickova V, Bartos R, Sames M, Pawlak I . Next generation sequencing of glioblastoma circulating tumor cells: non-invasive solution for disease monitoring. Am J Transl Res. 2021; 13(5):4489-4499. PMC: 8205800. View

Naryzhny S, Volnitskiy A, Kopylov A, Zorina E, Kamyshinsky R, Bairamukov V . Proteome of Glioblastoma-Derived Exosomes as a Source of Biomarkers. Biomedicines. 2020; 8(7). PMC: 7399833. DOI: 10.3390/biomedicines8070216. View

Gallego Perez-Larraya J, Paris S, Idbaih A, Dehais C, Laigle-Donadey F, Navarro S . Diagnostic and prognostic value of preoperative combined GFAP, IGFBP-2, and YKL-40 plasma levels in patients with glioblastoma. Cancer. 2014; 120(24):3972-80. DOI: 10.1002/cncr.28949. View

10.

Zhao H, Shen J, Hodges T, Song R, Fuller G, Heimberger A . Serum microRNA profiling in patients with glioblastoma: a survival analysis. Mol Cancer. 2017; 16(1):59. PMC: 5346242. DOI: 10.1186/s12943-017-0628-5. View

11.

Sasmita A, Wong Y, Ling A . Biomarkers and therapeutic advances in glioblastoma multiforme. Asia Pac J Clin Oncol. 2017; 14(1):40-51. DOI: 10.1111/ajco.12756. View

12.

Mao H, LeBrun D, Yang J, Zhu V, Li M . Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets. Cancer Invest. 2012; 30(1):48-56. PMC: 3799884. DOI: 10.3109/07357907.2011.630050. View

13.

Zill O, Banks K, Fairclough S, Mortimer S, Vowles J, Mokhtari R . The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients. Clin Cancer Res. 2018; 24(15):3528-3538. DOI: 10.1158/1078-0432.CCR-17-3837. View

14.

Ahmad Z, Arshad H, Hasan S, Fatima S, Idrees R, Aftab K . CNS neoplasms in Pakistan, a pathological perspective. Asian Pac J Cancer Prev. 2011; 12(1):317-21. View

15.

Malakhov N, Lee A, Garay E, Becker D, Schreiber D . Patterns of care and outcomes for glioblastoma in patients with poor performance status. J Clin Neurosci. 2018; 52:66-70. DOI: 10.1016/j.jocn.2018.03.006. View

16.

Ieva A, Magnussen J, McIntosh J, Mulcahy M, Pardey M, Choi C . Magnetic Resonance Spectroscopic Assessment of Isocitrate Dehydrogenase Status in Gliomas: The New Frontiers of Spectrobiopsy in Neurodiagnostics. World Neurosurg. 2019; 133:e421-e427. DOI: 10.1016/j.wneu.2019.09.040. View

17.

Xu Y, Zhong Z, Yuan J, Zhang Z, Wei Q, Song W . Collaborative overexpression of matrix metalloproteinase-1 and vascular endothelial growth factor-C predicts adverse prognosis in patients with gliomas. Cancer Epidemiol. 2013; 37(5):697-702. DOI: 10.1016/j.canep.2013.06.006. View

18.

He Z, Ping Y, Xu S, Lin Y, Yu S, Kung H . Lower MGMT expression predicts better prognosis in proneural-like glioblastoma. Int J Clin Exp Med. 2016; 8(11):20287-94. PMC: 4723787. View

19.

Sabha N, Knobbe C, Maganti M, Al Omar S, Bernstein M, Cairns R . Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas. Neuro Oncol. 2014; 16(7):914-23. PMC: 4057130. DOI: 10.1093/neuonc/not299. View

20.

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View